Quell Therapeutics Unveils New Scientific Advisory Board
Quell Therapeutics Ltd, a leader in engineered T-regulatory (Treg) cell therapies aimed at addressing immune-mediated diseases, has announced the establishment of its Scientific Advisory Board (SAB). This board brings together a distinguished group of experts in various fields including Treg cell biology, immunology, and organ transplantation. Their role is to provide invaluable scientific and clinical guidance as Quell Therapeutics continues to develop an industry-leading portfolio of CAR-Treg cell therapies.
Insights from the CEO
“We are thrilled to welcome such a talented group of individuals to our Scientific Advisory Board,” said Iain McGill, CEO of Quell Therapeutics. “The extensive experience and expertise they bring to the table in areas critical to our mission will be instrumental in enhancing our T-regulatory cell therapy platform and expediting our innovative therapies through clinical development.”
Meet the Scientific Advisory Board Members
The SAB is chaired by Professor Sir Robert Lechler, a prominent figure in clinical academia and transplant immunology. His leadership has been integral to many scientific institutions and initiatives worldwide. As a Non-Executive Director of NHS England, he also co-chairs the Board of SC1 London Life Sciences Innovation District.
Key Members of the SAB
- Professor Elmar Jaeckel, MD, Co-founder of Quell Therapeutics, also serves as the Medical Director for the Toronto Liver Transplant Program. His extensive research in organ transplantation and immune tolerance places him at the forefront of Quell's therapeutic pursuits.
- Professor Bruce L. Levine, PhD, an esteemed expert in cancer gene therapy at the University of Pennsylvania. He has a remarkable track record, including the co-invention of Kymriah, the first FDA-approved gene therapy for cancer.
- Professor Megan K. Levings, PhD, a leader in human immunology at the University of British Columbia, combines deep academic knowledge with groundbreaking research into Treg biology.
- Professor Peter A. Merkel, MD, MPH, a noted expert in autoimmune diseases at the University of Pennsylvania, focuses on developing new therapeutic approaches and advocating for patient-centered clinical trial designs.
- Dr. Dhavalkumar D. Patel, MD, PhD, Chief Scientific Officer at Sana Biotechnology, brings vital expertise in advancing the field of immunological therapeutics through his extensive industry experience.
About Quell Therapeutics
Quell Therapeutics stands at the forefront of developing engineered T-regulatory (Treg) cell therapies. The company's mission revolves around harnessing and optimizing the immune suppressive properties of Tregs to provide solutions for serious medical conditions related to the immune system.
The company utilizes its proprietary Foxp3 Phenotype Lock™ technology alongside a sophisticated multi-modular platform designed to enhance the persistence, potency, and stability of Treg cell therapies. This positions Quell's treatments for impressive efficacy compared to prior generations of therapies.
Pipeline and Innovations
Quell's primary candidate, QEL-001, is currently in the Phase 1/2 LIBERATE clinical trial, focusing on operational tolerance following liver transplantation. This innovative approach seeks to maintain liver health post-transplantation without requiring lifelong immunosuppressive medications. Furthermore, Quell is pursuing treatments for several autoimmune conditions including QEL-005 for complex rheumatic diseases, QEL-002 for Type 1 Diabetes, and QEL-003 for Inflammatory Bowel Disease — the latter developed in collaboration with AstraZeneca.
Contact Information
If you would like to learn more about Quell Therapeutics or get in touch:
Luke Henry, Chief Business Officer
Quell Therapeutics
Email: IR@quell-tx.com
For media inquiries: Mark Swallow, Sandi Greenwood, Erica Hollingsworth
MEDiSTRAVA
Email: Quell-Tx@Medistrava.com
For investors: Corey Davis
LifeSci Advisors
Email: cdavis@lifesciadvisors.com
Frequently Asked Questions
What is the purpose of the Scientific Advisory Board for Quell Therapeutics?
The SAB aims to provide expert guidance in Treg cell therapy, helping Quell advance its innovative treatment pipeline.
Who are the notable members of the Scientific Advisory Board?
Key members include Professor Sir Robert Lechler, Professor Elmar Jaeckel, and Professor Bruce L. Levine, all recognized leaders in their fields.
What is the significance of Quell's QEL-001 in clinical trials?
QEL-001 is being researched for its potential to promote operational tolerance in liver transplants, possibly eliminating the need for long-term immunosuppression.
How does Quell's technology differ from earlier Treg therapies?
Quell’s approaches leverage the Foxp3 Phenotype Lock™ technology, aiming for enhanced stability and therapeutic effectiveness compared to earlier methods.
Where can I find more information about Quell Therapeutics?
For more details, visit Quell's official website at www.quell-tx.com.
